crisis an open forum
play

American Pharmacists Association Addressing the COVID-19 Crisis: An Open Forum Webinar Series for Pharmacists May 21, 2020 American Pharmacists Association Michael D. Hogue, PharmD, FAPHA, FNAP Dean and Professor Loma Linda University

0 downloads 5 Views 2,73 MB Size Report
  1. American Pharmacists Association Addressing the COVID-19 Crisis: An Open Forum Webinar Series for Pharmacists May 21, 2020

  2. American Pharmacists Association Michael D. Hogue, PharmD, FAPHA, FNAP Dean and Professor Loma Linda University School of Pharmacy President, APhA Host and Moderator

  3. American Pharmacists Association Today’s Focus: Discuss antibody testing, how to evaluate antibody tests, and implications for pharmacists.

  4. American Pharmacists Association Paul C. Herrmann, MD, PhD Professor and Chair Department of Pathology and Human Anatomy Loma Linda University School of Medicine Guest Speaker

  5. American Pharmacists Association Daniel Zlott, PharmD, BCOP Vice President Professional Education Resources American Pharmacists Association Guest Speaker

  6. American Pharmacists Association Ilisa BG Bernstein, PharmD, JD, FAPhA Senior Vice President, Pharmacy Practice and Government Affairs American Pharmacists Association Subject Matter Expert: : Q&A

  7. American Pharmacists Association Format for Today’s Webinar 1:00 pm: Introductions 1:05 pm: Presentation by Dr. Daniel Zlott, Vice President, Professional Education Resources, American Pharmacists Association 1:15 pm: Presentation by Dr. Paul Herrmann, Professor and Chair for the Department of Pathology and Human Anatomy, Loma Linda University School of Medicine 1:25 pm: Open Forum: A Minute for Your Thoughts 1:50 pm: Wrap Up: Review of APhA’s Ongoing Activities and What’s Coming

  8. American Pharmacists Association Presentation by Dr. Daniel Zlott An overview of COVID-19 infection and the immune response

  9. American Pharmacists Association Overv rview of COVID-19 Vir irus • COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – for the sake of simplicity, we’ll call it the COVID -19 virus • The COVID-19 virus is an enveloped RNA virus • The COVID-19 virus consists of 1 • Spike proteins (S protein) • Envelope (lipid membrane) • Envelope (E) and Membrane (M) proteins • Nucleocapsid • Nucleoproteins (N protein) • Genetic material (RNA) • Miscellaneous proteins • Non-structural proteins (nsp) 3D Printed Model of COVID-19; Image Credit: NIAID-RML • Accessory proteins (ORF, and others) 1. Mousavizadeh, et al. J Microbiol Immunol Infect. 2020; DOI: https://doi.org/10.1016/j.jmii.2020.03.022

  10. American Pharmacists Association COVID-19 Antigens • There are a number of potential epitopes that have been confirmed or are hypothesized to generate an immune response 1,2 : • S protein • N protein • M protein • Nsp3, nsp4 • ORF3a, ORF8 • These epitopes have been confirmed or hypothesized to generate both T- and B-cell responses 1,2 • For the purposes of today’s discussion, we will be focusing on B-Cell responses Scanning electron migrograph of SARS-CoV-2; Image Credit: NIAID-RML 1. Grifoni, et al. Cell Host & Microbe. 2020; DOI: https://doi.org/10.1016/j.chom.2020.03.002 2. Grifoni, et al. Cell. 2020; DOI: https://doi.org/10.1016/j.cell.2020.05.015

  11. American Pharmacists Association General Review of Antibody Development Understanding antibody development 1 : • Antibodies are produced by activated B-cells (also called plasma cells) • B-lymphocytes recognize their targets through immunoglobulins present on the cell surface (B-cell receptor) • Once a B-lymphocyte recognizes its target, it must also be activated by CD4+ T-cells (helper T-cells), which secrete B-lymphocyte growth factors • Activated B-cells become plasma cells or memory B-cells • Each plasma cell makes a single type of antibody • There are 5 general classes of antibody (immunoglobulins) • IgA • IgD • IgE • IgM • IgG 1. Zlott, et al. ‘Function and Evaluation of the Immune System’, in Dipiro, et al. Pharmacotherapy: A Pathophysiologic Approach, 11 th Ed. McGraw Hill, 2019

  12. American Pharmacists Association General Review of Antibody Development • Understanding antibody development 1 : • It takes time to develop an antibody response once exposed to antigen 1 • IgM: Initial antibody produced upon initial exposure to antigen • IgM appears 4-7 days after initial exposure, and peaks 7-10 days after initial exposure • IgG: Longer term antibody produced upon initial exposure – provides long term protection against pathogen • IgG appears 7-10 days after initial exposure, and peaks 10-14 days after initial exposure • Upon re-exposure, memory B-cells rapidly reactivate plasma cells, which produce IgG, Image: Immunoglobulin response curve upon exposure to Dengue Fever. 2 neutralizing pathogen 1. Zlott, et al. ‘Function and Evaluation of the Immune System’, in Dipiro, et al. Pharmacotherapy: A Pathophysiologic Approach, 11 th Ed. McGraw Hill, 2019 2. Guzman, et al. Nature Reviews Microbiology 2010;8:S7-S16.

  13. American Pharmacists Association Do People Generate an Antibody Response to COVID-19? 19? • Yes! • A cross-sectional study from 3 hospitals which included 285 pts demonstrated that 100% of pts develop either IgM, IgG, or both within 19 days of symptom onset • All pts were confirmed to be COVID-19+ by PCR • Serum Ig levels tested by ELISA Figure 1a from Long, et al. 1 1. Long, et al. Nature Medicine . 2020; DOI: https://doi.org/10.1038/s41591-020-0897-1

  14. American Pharmacists Association Presentation by Dr. Paul Herrmann An overview of how antibody testing works and considerations for pharmacists

  15. American Pharmacists Association Enzyme-Linked Im Immunosorbent Assay (E (ELISA) socratic.org

  16. American Pharmacists Association Lateral Flo low Test antibioticresearch.org.uk

  17. American Pharmacists Association In Instrument Validation Must Demonstrate: • Precision • Accuracy • Reproducibility • Limits of Detection/Range • Correlation to Existing Method • Relevant Reference Range

  18. American Pharmacists Association

  19. American Pharmacists Association COVID-19 IgM/IgG Testing within 5 days of Positive PCR COVID-19 IgM/IgG Testing within 14 Days of Positive PCR

  20. American Pharmacists Association Unusual Regulatory ry Climate • Ordinarily a test is developed by a company. Then the FDA evaluates and approves it after extensive testing. Clinical labs do a quick validation to make sure everything is working correctly on site. • Due to current situation, FDA issued Emergency Use Authorization (EUA). High complexity CLIA certified labs just inherited all the work, liability and risk of what FDA used to do for us. • Antibody testing was turned loose by FDA even before EUA issuance. Even more imperative that lab validation be performed carefully and correctly.

  21. American Pharmacists Association Fin inding a Good Test

  22. American Pharmacists Association Tim imeline for Bri ringing in in a Lab Test Buy Install Validate Go Live Monitor New Test Don’t forget there will also need to be a supply chain for : reagents and supplies for instrument specimen collection materials staff to run the test in addition to everything else they were already doing

  23. American Pharmacists Association Polling Question My pharmacy practice site is considering offering antibody testing when it becomes available: A. Yes B. No C. Not applicable to my practice

  24. American Pharmacists Association Open Forum Ground Rules • Use the Questions field on the GoToWebinar toolbar to submit comments and questions related to the topic discussion • Individuals whose submissions are selected will be asked by the moderator to state the comment or question for the audience. The line for the individual will be unmuted to read their comment or question. • To maximize the number of questions/comments addressed, a 60-second time limit will be in effect for everyone to state their question or comment. • We will try to get to as many comments and questions as possible. We have created a new forum for COVID-19 discussions where further discussion post-webinar. Information on participating in this forum will be provided at the end of the open forum.

  25. American Pharmacists Association Open Forum Discussion: A Minute for Your Thoughts Comments, Questions, Feedback

  26. American Pharmacists Association Review of APhA’s Ongoing Activities and What’s Coming

  27. American Pharmacists Association NEW Episodes – APhA’s 15 on COVID -19 An education series designed to help you sort COVID-19 fact from fiction. Each episode is 15-20 minutes and provides CPE. Episode 16: Anticoagulation in COVID-19 http://elearning.pharmacist.com/products/6106 /15-on-covid-19-05-14-2020-anticoagulation/ Episode 17: Antibody Development and Reinfection http://elearning.pharmacist.com/products/6110 /15-on-covid-19-05-18-2020-antibody- development-and-reinfection

  28. American Pharmacists Association Check out the practice resources here • COVID-19 Fraudulent Medical Products and Scams • Demystifying Testing for SARS-CoV-2 Virus: Frequently Asked Questions • Vaccines in Development for COVID-19 • New resources weekly!

Recommend Documents


crisis an open forum webinar series for
Crisis: An Open Forum Webinar Series

American Pharmacists Association Addressing the COVID-19 Crisis: An Open

nsp o nsp open forum pen forum
NSP O NSP Open Forum pen Forum NSP

U.S. Department of Housing and Urban Development NSP O NSP Open Forum pen

nsp o nsp open forum pen forum
NSP O NSP Open Forum pen Forum NSP

U.S. Department of Housing and Urban Development NSP O NSP Open Forum pen

nsp o nsp open forum pen forum
NSP O NSP Open Forum pen Forum NSP

U.S. Department of Housing and Urban Development NSP O NSP Open Forum pen

open house open house open house open house on on on on
Open house Open house Open house

Open house Open house Open house Open house on on on on on on on on

covid 19
COVID-19 HOW TO COMMUNICATE DURING

COVID-19 HOW TO COMMUNICATE DURING THE COVID-19 CRISIS CRISIS COMMUNICATIONS

civil society forum on the global food crisis outcome
Civil Society Forum on the Global Food

Civil Society Forum on the Global Food Crisis: Outcome Document 16 May 2008

open forum on pan european instant payments
Open Forum on Pan-European Instant

Open Forum on Pan-European Instant Payments Milan 7 th June 2016 Open Forum on

two views
Two Views 1 It's been proven now that

Two Views 1 It's been proven now that the crisis is not a Greek crisis. The

2009
2009 FORUM 3 The current financial

PACDEFF 2009 FORUM 3 The current financial crisis and its effect on training

first presentation of early data for pembrolizumab mk
First Presentation of Early Data for

NEWS RELEASE First Presentation of Early Data for Pembrolizumab (MK-3475),

nephritis
Nephritis Brad H. Rovin, MD Professor

New Treatment Options for Lupus Nephritis Brad H. Rovin, MD Professor of

investor presentation
Investor Presentation May 2019 1

Investor Presentation May 2019 1 Forward-Looking Statements This

antibody mediated therapy approaches in hiv 1 infection
Antibody-mediated therapy approaches in

Antibody-mediated therapy approaches in HIV-1 infection Florian Klein Arevir

g ran forsberg ceo
Gran Forsberg, CEO January 2020 Safe

We want to save patients with severe cancer and autoimmune diseases Clinical

alopexx pharmaceuticals
Alopexx Pharmaceuticals Founded in

A L O P E X X Pharmaceuticals, LLC Antibody Targeting of Poly N-Acetyl

mologic partnering
Mologic partnering wit ith the In

Mologic partnering wit ith the In Institut Pasteur de Dakar Home of the

designed antibodies as weapons
Designed Antibodies as Weapons against

Designed Antibodies as Weapons against Infectious Diseases Jan Terje Andersen

j a n u a r y 20 1 8 sab team amp technology together for
J a n u a r y 20 1 8 SAB Team &

J a n u a r y 20 1 8 SAB Team & Technology Together for 15+ Years

immunoyeast amp the antibody discovery toolkit specific
immunoYeast & The Antibody

immunoYeast & The Antibody Discovery Toolkit Specific Antibodies on

antibody generation system
Antibody Generation System Maturation,

Antibody Generation System Maturation, Selection and Production in CHO Cells

production of homogeneous adcs with combination warheads
Production of Homogeneous ADCs with

Production of Homogeneous ADCs with Combination Warheads and Bispecifics